Cite
HARVARD Citation
Workman, P. et al. (n.d.). Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor. European journal of cancer. pp. S35-. [Online].